Cardiovascular Management in Pregnancy: Antithrombotic Agents and Antiplatelet Agents

Circulation. 2015 Oct 6;132(14):1354-64. doi: 10.1161/CIRCULATIONAHA.114.003902.
No abstract available

Keywords: anticoagulation; pregnancy; thrombosis.

Publication types

  • Review

MeSH terms

  • Abruptio Placentae
  • Anticoagulants / adverse effects
  • Anticoagulants / classification
  • Anticoagulants / pharmacokinetics
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome / complications
  • Antiphospholipid Syndrome / drug therapy
  • Comorbidity
  • Contraindications
  • Dose-Response Relationship, Drug
  • Female
  • Fetal Growth Retardation
  • Fetus / drug effects
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / pharmacokinetics
  • Fibrinolytic Agents / therapeutic use
  • Heart Valve Prosthesis
  • Hematologic Agents / adverse effects
  • Hematologic Agents / therapeutic use*
  • Hemorrhage / chemically induced
  • Hemorrhage / prevention & control
  • Humans
  • Infant, Newborn
  • Maternal-Fetal Exchange
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Platelet Aggregation Inhibitors / therapeutic use
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Preservatives, Pharmaceutical / adverse effects
  • Preservatives, Pharmaceutical / pharmacokinetics
  • Thrombophilia / drug therapy
  • Thrombophilia / etiology

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Hematologic Agents
  • Platelet Aggregation Inhibitors
  • Preservatives, Pharmaceutical